cyrilzakka/clinical-trials huggingface dataset:
Risk Factors and Reasons for Cancellation Within 24 Hours of Scheduled Elective Surgery in an Academic Medical Centre

The Operating Theatre (OT) is the largest cost centre as well as the main revenue generator in most hospitals. One of the common problems affecting optimal OT utilization is the cancellation of scheduled surgeries. The goal of this study was to identify factors associated with cancellation within 24 hours of scheduled surgeries in a tertiary hospital

The Operating Theatre (OT) is the largest cost centre as well as the main revenue generator in most hospitals. The operating theatre involves significant resources - materials, medications and manpower. One of the common problems affecting optimal OT utilization is the cancellation of scheduled surgeries. This results in a significant waste of resources, especially when cancellation occurs within 24 hours of the scheduled surgery, when it is too late to arrange replacement surgery. Cancellation also impacts the patient and their families.

Reported cancellation rates range between 5% to 40%. Reasons for cancellations vary, including patient factors, surgeon factors, and system issues relating to the preoperative anaesthesia assessment clinic attendance, the surgery itself, and the availability of post-surgical care facilities. Between 60% to 90% of cancellations have been reported to be potentially avoidable.

The goal of this study was to identify factors associated with cancellation within 24 hours of scheduled surgery in a tertiary academic hospital, and the reasons for cancellation, with the goal of identifying areas for intervention to reduce avoidable surgery cancellations and reduce unnecessary waste.

Eligibility Criteria:
Adult patients (age 18 years and older) who were scheduled for elective surgery at the Singapore General Hospital main operating theatre or ambulatory surgical centre, regardless of surgical discipline, or residency, were included in the study. Only the first surgery in the study period was included if a patient had multiple surgeries over this period. Minor surgeries under local anaesthesia were also excluded. We excluded those without previous admissions in the past 3 years prior to the surgery, as data for chronic disease history and healthcare utilization patterns were not available for these patients
Evaluation of Long-term Isokinetic Training of Knee Joint

The goal of this clinical trial is to assess the effectiveness of isokinetic rehabilitation training under optimal stiffness in patients undergoing knee joint rehabilitation. The main questions it aims to answer are:

* Does isokinetic training under optimal stiffness lead to greater force exertion compared to traditional bodyweight training?
* What are the long-term (6-week) effects of isokinetic training under optimal stiffness on joint flexibility and muscle strength? Researchers will compare the effects of isokinetic training under optimal stiffness to traditional bodyweight training to see if isokinetic training produces superior improvements in muscle strength, flexibility, and overall functional recovery.

Participants will:

* Perform regular training sessions using a portable knee joint isokinetic trainer, customized to their optimal stiffness for maximum force exertion.
* Engage in a 6-week rehabilitation program, with assessments at the beginning, and end of the study to evaluate changes in muscle strength, and functional recovery.


Eligibility Criteria:
Inclusion Criteria:

1. Age between 20-60 years.
2. Patients with unilateral anterior cruciate ligament (ACL) rupture, with or without meniscus injury.
3. Postoperative period of 3-6 months.
4. No restriction in knee extension or flexion movements.

Exclusion Criteria:

1. Patients with major diseases or conditions such as coronary heart disease, myocardial infarction, heart failure, cerebral infarction, cerebral hemorrhage, or malignant tumors.
2. Pregnant or breastfeeding women and other special populations.
3. Patients who refuse to sign the informed consent form or are unable to complete the entire study process.
4. Patients currently infected with human immunodeficiency virus (HIV), or with a history of infectious hepatitis B or C.
5. Patients with concurrent medical issues, including but not limited to: (1) Uncontrolled hypertension (systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥95 mmHg), congestive heart failure (New York Heart Association functional classification of stage III or IV). (2) Patients with mental incapacity or an inability to comprehend the study requirements.
The Relationship Between CD138 Count of Endometrium and Reproductive Outcome

It's well known, endometritis affects reproductive outcomes. Though CD138 counting as one new diagnosis measure for endometritis, diagnostic criterion of this measure isn't consistent. And if the CD138 counting is correlation to the outcome of reproductive is not clear.

Firstly, This study aims to explore the relationship between endometrial CD138 count and pregnancy outcome following frozen embryo transfer in natural cycles. Secondly , the investigators want to find a cut-off value which is related to reproduction outcome.


Eligibility Criteria:
Inclusion Criteria:

* age between20 and 38 years;
* regular menstrual cycles;
* body mass index (BMI) ranged from 18 to 25

Exclusion Criteria:

* uterine abnormalities;
* intrauterine adhesions（moderate - severe）, advanced endometriosis, adenomyosis, untreated hydrosalpinx, uterine fibroids (submucosal fibroids, nonmucosal fibroids \>4.0 cm and/or endometrial pressure)
A Safety and Tolerability Study of 10XB-101 Injection in Adult Subjects With Submental Fat

The purpose of this research study is to determine the safety and efficacy of 10XB-101 vs. vehicle (placebo) for adults with excessive submental fat (SMF).


Eligibility Criteria:
Inclusion Criteria:

* Subject is a male or non-pregnant female 18 to 65 years old.
* Subject has provided written informed consent.
* Subject has qualifying Submental Fat evaluation score.
* Subject has had a stable body weight for the past 6 months prior to starting study.
* Subject is willing to undergo test article injections as directed, comply with study instructions, and commit to all follow-up visits for the duration of the study.

Exclusion Criteria:

* Subject is pregnant, lactating, or is planning to become pregnant during the study.
* Subject has loose skin in the submental area, diffuse SMF, or prominent platysmal bands at rest that may interfere with evaluation of localized fat, in the opinion of the investigator.
* Subject has had any prior treatment for SMF (e.g., deoxycholic acid, cryotherapy, liposuction, surgery).
* Subject has any medical condition that affects clotting and/or platelet function
* Subject has a history of allergy or sensitivity to polidocanol or any of the other ingredients in the test articles.
Ventilator-driven Alveolar Recruitment Maneuver

During laparoscopic surgery, gas infiltration and head down position cause pulmonary atelectasis. Alveolar recruitment maneuvers are beneficial in reopening collapsed alveoli and improving lung mechanics. Ventilator-driven Alveolar recruitment maneuvers may restore lung volume but it remains unknown which method is most effective. The primary aim was to compare the efficacy of two ventilator-driven ARMs method using incremental tidal volume or positive end expiratory pressure(PEEP) until plateau pressure 30 cmH20 (within driving pressure 20 cmH20).

General anesthesia promotes the formation of atelectasis, which negatively impacts respiratory function and may be associated with subsequent pulmonary complications. Especially, during laparoscopic surgery, gas infiltration and head down position cause pulmonary atelectasis. Alveolar recruitment maneuvers are beneficial in reopening collapsed alveoli and improving lung mechanics, suggesting that performing an Alveolar recruitment maneuvers after intubation, circuit disconnection, position change, intraabdominal gas infiltration.

Conventional manual ARM is performed by sustained lung inflation using the reservoir bag on the anaesthesia machine with the adjustable pressure-limiting valve set to the desired inflation pressure. However, the manual ARM can lead to brief loss of positive pressure when switching back to the ventilator circuit, which results in re-collapse of alveoli. For this reason, investigators try to compare the methods of the ventilator-driven ARM.

Eligibility Criteria:
Inclusion Criteria:

* patients who receive laparoscopic surgery in trendelenberg position

Exclusion Criteria:

* Patients who are simultaneously participating in other studies
* Patients who are scheduled to leave the intensive care unit after surgery
* Patients with obstructive or restrictive pattern of Severe or moderate grade on Pulmonary function test
* High risk in cardiovascular events (expected postoperative cardiovascular event \> 5%)
* Patients with emphysema confirmed by imaging test
* patients with obesity BMI \> 35 kg / m2
Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors

The purpose of this study is to determine the safety and tolerability of VCN-01 either administered alone or in combination with Abraxane®/Gemcitabine, and to determine the recommended phase II dose of VCN-01 alone or in combination with Abraxane®/Gemcitabine.

The study consists of three parts:

* Part I is a dose escalation study to determine the safety and tolerability of a single intravenous injection of VCN-01 alone
* In Part II the safety and tolerability of the two highest VCN-01 tolerable doses from part I will be evaluated in combination with Abraxane®/Gemcitabine.
* In Part III the safety and tolerability of the two highest VCN-01 tolerable doses from part I will be evaluated in combination with Abraxane®/Gemcitabine in a "delayed" schedule compared with Part II.

Eligibility Criteria:
Inclusion Criteria:

* Male/Female patients aged 18 years or over
* Patients must provide written informed consent
* Part I: Patients with histologically confirmed, locally advanced or metastatic solid tumors. Part II and Part III: Patients with histologically confirmed, pancreatic adenocarcinoma for which the established therapy is Abraxane®/Gemcitabine (clinical standard of care)
* Life expectancy above 3 months
* Patients willing to comply with treatment follow-up
* ECOG Performance status 0 or 1
* Adequate baseline organ function (hematologic, liver, renal and nutritional)
* Use a reliable method of contraception in fertile men and women

Exclusion Criteria:

* Active infection or other serious illness or autoimmune disease
* Treatment with live attenuated vaccines in the last three weeks
* Known chronic liver disease (liver cirrhosis, chronic hepatitis)
* Treatment with another investigational agent within its five half-lives prior to VCN-01 infusion
* Viral syndrome diagnosed during the two weeks before inclusion
* Chronic immunosuppressive therapy
* Concurrent malignant hematologic or solid disease
* Pregnancy or lactation. Patients must agree to use effective contraception or be surgically sterile.
* Patients receiving full-dose anticoagulant / antiplatelet therapy
* Adequate levels of neutralizing antibodies against adenovirus
* Patients with Li Fraumeni syndrome or with previous known retinoblastoma protein pathway germinal deficiency
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

The purpose of this study is to assess the safety and efficacy of avelumab in combination with other anti-tumor agents as a maintenance treatment in participants with bladder cancer.


Eligibility Criteria:
Inclusion Criteria:

* Participants with histologically confirmed, unresectable locally advanced or metastatic urothelial carcinoma. Both transitional cell and mixed transitional/non- transitional cell histologies are allowed, but transitional cell carcinoma must be the predominant histology
* Participants has documented Stage IIIA/IIIB with N1-N3, or Stage IV disease (per American Joint Committee on Cancer/International Union for Cancer Control Tumor Node Metastasis system, 8th edition) at the start of first line chemotherapy.
* The last dose of first line chemotherapy must have been received no less than 4 weeks, and no more than 10 weeks, prior to randomization in the present study
* Estimated life expectancy of at least 3 months
* Participants without progressive disease as per RECIST v1.1 guidelines following completion of 4 to 6 cycles of 1L chemotherapy. Eligibility based on this criterion will be determined by Investigator review of pre chemotherapy and post chemotherapy radiological assessments (CT/MRI scans).
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
* Adequate hematological, hepatic, and renal function as defined in the protocol
* Other protocol defined inclusion criteria could apply

Exclusion Criteria:

* Participants with prior immunotherapy with Interleukin-2 (IL-2), IL-15, interferon alfa (IFN-α), or an anti programmed death receptor-1 (PD-1), anti programmed death-ligand 1 (PD-L1), anti PD-L2, anti CD137, or cytotoxic T cell lymphocyte-4 (CTLA-4) antibody (including ipilimumab), anti TROP2, anti-T-cell-immuno-receptor with Ig and ITM domains (anti-TIGIT) any other antibody or drug specifically targeting T cell costimulation or immune checkpoint pathways, agents targeting Nectin-4, or any of the investigational drugs used in combination with avelumab.
* Participants with active infection 48 hours before randomization requiring systemic therapy
* Participants with known prior or suspected hypersensitivity to study drugs or any component in their formulations
* Participants with prior adjuvant or neoadjuvant systemic therapy within 12 months of randomization
* Participants with vaccination within 4 weeks of the first dose of study treatment and while on trial is prohibited except for administration of inactivated vaccines (for example, inactivated influenza vaccines) administered \>= 2 weeks prior first dose of study treatment. All severe acute respiratory syndrome coronavirus (SARS-CoV-2) vaccines approved or authorized by local Health Authorities are allowed
* Other protocol defined exclusion criteria could apply
Effects of a Web Based Education Programme About Sexuality Aimed at Nurses That Care for Patients With Cancer

The purpose of the SexCan - WebEd Nurse study is to evaluate the effect of a five week online university course, "Bring it up - Assessment and support of patients' sexuality in cancer nursing", aimed at cancer nurses, on occupational self-efficacy and attitudes towards addressing sexuality with patients.

Cancer nurses attending the course will be recruited. Effects will be used with a pre-post design at two occasions or until we reach 15 participants. Survey data will be collected at baseline and two times post the course. Qualitative interviews with participants will also be performed as well as observational data from the seminars in the course.

The participants' ward managers will also be invited to qualitative interviews considering how to implement the nurses' new knowledge clinically.

Eligibility Criteria:
Inclusion Criteria:

- Registered nurses working as a contact nurses in cancer care who are admitted to the intervention university course.

Exclusion Criteria:

- N/A.
Homeopathy for Prevention of Atrial Fibrillation After Aortocoronary Bypass Surgery

After heart surgery, about 30% of patients suffer from atrial fibrillation. Patients are randomized into two groups receiving either potentized Strychnos Nux vomica or placebo under double blind conditions. Postoperatively, ECGs are done to monitor cardiac rhythm.

Preoperatively, patients receive potentized Nux vomica or placebo sublingually. Then, patients are observed regarding atrial fibrillation postsurgical. The difference between the group of patients with and without nux vomica is recorded.

Eligibility Criteria:
Inclusion Criteria:

* Patients before elective Heart valve - or aortocoronary by pass surgery with heart-lung-machine.

Exclusion Criteria:

* Pregnant patients
* Patients with preoperative atrial fibrillation and/or hyperthyreosis
Clinical Assessment of Spatial Neglect Following Stroke

Spatial neglect (SN) is a common heterogeneous cognitive affliction that predicts poor recovery after a stroke. It is important to identify SN so alliviating actions can be initated. Results of this cross-country study between Iceland and Lithuania should provide information on how to best identify SN in clinical care.

Spatial neglect (SN) is a common disorder following stroke, adversely affecting recovery. SN often involves associated symptoms, including anosognosia, extinction, difficulties with sustained attention and problems with emotional processing. Correct identification of SN and associated problems is essential for initiating alleviating strategies and for measuring progress. Several assessment tools exist, but psychometric testing has mostly been conducted in non-dynamic environments; a single country or culture. Thus non-transferable to a wider context and ward-based care. To optimize identification of SN and develop procedures for diverse healthcare settings, this cross-country study includes patients from Iceland and Lithuania. We will seek to maximize the clinical utility by avoiding exclusion of patients, e.g., with psycholinguistic difficulties and multiple strokes. We will: a) use behavioral SN assessment and visuo-graphic tests to validate a newly developed SN tool that incorporates many aspects of SN that are currently not addressed in conventional tests, b) validate integration of an additional component into the National Institute of Health Stroke Scale as a screening tool to identify SN, and c) evaluate differences in clinical characteristics between patients with left- and right-sided SN, and patients with and without SN.

Eligibility Criteria:
Inclusion Criteria:

* Stroke diagnosis confirmed by results of CT/MRI.
* Lives in Iceland or Lithuania.
* 18 year or older.
* Informed consent provided by patient or proxy.

Exclusion Criteria:

• Patients receiving end-of-life care
Immune Profiling for Cancer Immunotherapy Response

In patients clinically treated with FDA-approved immunotherapy the investigators will assess the predictive value of pre- and on-treatment 1) immune-methylation profiling across cancer types, and 2) immune-methylation profiling and cytokine profiling within cancer types.


Eligibility Criteria:
Inclusion Criteria:

* Cancer patients receiving or will receive immunotherapy under FDA- approved indication (e.g. checkpoint inhibitor therapy with pembrolizumab, nivolumab, or ipilimumab, or cellular immunotherapy).
* Participants are eligible regardless of the type of prior therapy (i.e. prior immunotherapy treated participants can be included).

Exclusion Criteria:

* Pregnant women/fetuses/neonates
* Prisoners
* Decision-impaired individuals
Effect of Phytoecdysterone Administration in Subjects With Prediabetes

Prediabetes is the term used for people whose glucose levels do not meet the criteria for diabetes but are too high to be considered normal. This is defined by the presence of blood glucose between 100-125 mg / dL, values per glucose tolerance curve of 140-199mg / dL and/or HbA1c 5.7-6.4%. Prediabetes should not be considered as a clinical entity in itself, but as a risk factor for diabetes and cardiovascular disease (CVD). Prediabetes is associated with obesity (especially abdominal or visceral obesity), dyslipidemia with elevated triglycerides and/or low HDL cholesterol, and hypertension.

Subjects with a diagnosis of prediabetes are included according to the criteria of the American Diabetes Association in its version 2019, between 30 and 60 years old residents of the city of Guadalajara, Jalisco, Mexico who come to clinical nutrition consultation in the University Hospital Fray Antonio Alcalde from the city of Guadalajara, Jalisco, Mexico.

The study design is a randomized, randomized clinical trial with a control group in two groups: an intervention group with ecdysterone 300mg every 24 hours for 12 weeks (approximately 90 days) and an approved placebo control group (magnesia stearate) ) at 300mg every 24 hours for 12 weeks (approximately 90 days).

Eligibility Criteria:
Inclusion Criteria:

1. - Fasting Plasma Glucose between 100 mg/dL (5.6 mmol/L) to 125 mg/dL (6.9 mmol/L)
2. - Oral Glucose Tolerance Test 140 mg/dL (7.8 mmol/L) to 199 mg/dL (11.0 mmol/L)
3. - A1C 5.7-6.4% (39-47 mmol/mol).
4. - Body Mass Index \>25 kg/m2 or \>23 kg/m2
5. - Adults who have one or more of the following risk factors:

   * First-degree relative with diabetes
   * High-risk race/ethnicity
   * History of CVD
6. - Blood Pressure \<140/90 mmHg without therapy for hypertension
7. - HDL cholesterol level \<0.35 mg/dL (0.90 mmol/L) and/or a triglyceride level \>0.250 mg/dL (2.82 mmol/L)

Exclusion Criteria:

1.- Pregnant women or lactic period 2- Patients with some other chronic degenerative disease like diabetes mellitus 2 with pharmacologic treatment.

3.- Hypertension 4.- Cancer, 5.- Hyperthyroidism 6.- Hypothyroidism 7.- Immunologic disease 8.- Kidney disease 9.- Hepatic disease 10.- Cardiovascular disease 11- Abaqus activity 12.-Alcoholic activity.
Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular AMD.

To evaluate the visual outcome, number of injections and visits, and the effect of mental status of a treat and extend regimen in managing neovascular age-related macular degeneration with intravitreal ranibizumab.

Treat and Extend Regimen (TER) may contribute to the improvement to a patients' mentality, since the treatment intervals are extended if there were no signs of recurrence. Therefore, we have planned to examine the psychological impact of TER using Hospital Anxiety and Depression Scale (HADS), in addition to the improvement of visual acuity and central retinal thickness.

Eligibility Criteria:
Inclusion Criteria:

* Signed informed consent form
* Male or female of aged 50 years or older
* Typical AMD and PCV patients
* BCVA of 24 letters or over

Exclusion Criteria:

* Total lesion area of \>12 DA or \>30.5 mm2
* The existence of subretinal hemorrhage area constituting ≥50% of total lesion area
* The existence of scar or fibrosis area constituting ≥50% of total lesion area
* The existence of RPE tear
* Prior treatment for wet AMD
* History of vitrectomy surgery, submacular surgery, or other surgical intervention for AMD
* The pregnant or lactating woman